May 2018

New Product - Odomzo

Odomzo (sonidegib) is a selective Smoothened (Smo) antagonist. Smo is a G-protein coupled receptor-like molecule that positively regulates the Hedgehog (Hh) signal transduction pathway, which is linked to the pathogenesis of several types of cancer including basal cell carcinoma (BCC). Odomzo is indicated for the treatment of adults with: locally advanced BCC who are not amenable to curative surgery or radiation therapy; metastatic BCC. Odomzo is contraindicated in women who are pregnant or breastfeeding, and women of childbearing potential (unless two reliable methods of contraception are used during treatment and for 20 months after the last dose). Odomzo 200 mg tablets are available in packs of 30.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au